Lundbeck starts phase 1 trials of Lu AA24530 for depression

New York, Dec. 12 - Lundbeck said it has begun phase 1 clinical studies of Lu AA24530 for depression.

The research will look at tolerability and the pharmacokinetic profile of the drug.

The Copenhagen, Denmark, pharmaceutical company said it selected Lu AA24530 because of its "convincing effect" in preclinical animal models, suggesting fast onset of action and increased efficacy in the treatment of depression.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.